Guardant Health, Inc. (GH): Entry into a Material Definitive Agreement

Guardant Health, Inc. (GH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032 PALO ALTO, Calif. November 11, 2026—(BUSINESS WIRE)—Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its inten

Event · Offering · proposed
Instrument
convertible senior notes due 2032
Gross proceeds
$500.0 million
Maturity
May 15, 2032
Also in this documentOffering · $50M

Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.

Original reporting
Published Nov 16, 2026, 9:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GH
Bearish
high confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GHBearishMed
01

Why it matters

This is a capital-structure event: GH is raising up to $550M in convertible senior notes due 2032, with redemption features tied to the stock price versus the conversion price, and it intends to use proceeds for partial repurchase of its 0% convertible notes due 2027 plus capped call costs.

02

Market read

Traders should focus on convertible pricing expectations, dilution/hedge dynamics, and any concurrent 2027 note repurchase terms that could affect near-term equity and credit spreads.

03

What to watch

The article flags that option counterparties and hedged holders may buy GH shares and unwind hedges around pricing, which can temporarily support the stock even as the financing is announced.

Relevance 6/10Novelty 8/10Timing: after-hours filing today, ahead of any pricing/settlement of the convertible notes

Background

The SEC 8-K Item 1.01/2.03/3.02/8.01 reports Guardant Health’s entry into a material definitive agreement tied to a proposed convertible notes offering and related capped call and repurchase plans.

Company-level read

Ticker impact

$GHBearishHigh confidence
Context

Guardant Health plans a $500M convertible notes offering due 2032, with up to $50M greenshoe, plus capped calls and potential 2027 note repurchases.

Expected impact

Likely near-term volatility as markets price the convertible issuance, potential dilution, and any concurrent 2027 note repurchase activity.

Evidence & confidence

The 8-K details the size, structure, conversion/redemption mechanics, and stated intended uses of proceeds, which directly affect GH’s capital structure and equity risk.

Market effects

Precision oncology and biotech issuers may see read-through demand for convertible financing and hedging structures.

US small/mid-cap biotech credit and equity derivatives may experience localized hedging flows around pricing.

Limited direct global impact, but convertible issuance mechanics can influence broader risk sentiment toward growth biotech funding.

Counterpoint

If the capped calls and any 2027 repurchases are executed aggressively, the net equity dilution risk could be more contained than typical convertibles, reducing downside.

Key entities

  • Guardant Health, Inc.

    Subject of the 8-K, proposing a $500M convertible senior notes offering due 2032 with up to $50M additional notes.

  • 0% convertible senior notes due 2027

    Existing convertible debt GH expects to repurchase partially using proceeds from the new offering.

  • Capped call transactions

    Privately negotiated capped call overlays intended to reduce potential dilution upon conversion.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.